Breast Cancer
News
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancer
Key clinical point: Adjuvant capecitabine improves outcomes in women with HER2-negative breast cancer who have residual invasive disease after...
News
High risk for getting breast cancer linked with low risk of metastasis
Key clinical point: High risk of breast cancer based on specific prediction models was associated with favorable tumor prognosticators and reduced...
News
Die not yet cast for lymphazurin and methylene blue dye
Key clinical point: Contrary to prior studies, lymph node positivity was higher with lymphazurin than methylene blue in patients with early breast...
News
What’s anticipated at SABCS 2015?
Conference Coverage
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
Among women diagnosed with breast cancer in their 70s, more will die from cardiovascular disease than from their malignancy.
News
Racial differences found in neoadjuvant chemo, pCR rates for breast cancer
Key clinical point: Non-white Hispanic, Asian, and black women are likelier to receive neoadjuvant chemotherapy than are white women for breast...
News
No benefit from dual anti-HER2 blockade in early breast cancer
Key clinical point: Adjuvant lapatinib and trastuzumab resulted in similar disease-free survival, compared with trastuzumab alone in early HER2-...
News
No racial disparity in appropriate use of Oncotype DX
Key clinical point: ODX testing is more likely to be administered to nonblack women with node-positive disease than to black women. Major finding...
Conference Coverage
Antibody drug conjugate induces responses in heavily pretreated TNBC
Key clinical point: Conjugating a metabolite of irinotecan to an antibody allows targeted delivery of the otherwise highly toxic drug. Major...
From the Editor
Balancing clinical and supportive care at every step of the disease continuum
News
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
A novel pan-AKT inhibitor shrinks tumors in patients harboring a mutation in AKT1.